And that is the whole point. To date much of prescribed cannabinoids are either in tincture form, unreliable dosing and requiring refrigeration with short shelf life as it degrades over time even if kept carefully refrigerated, or soft cap form which has similar problems. Both are absorbed in the stomach where it is effected by acidity and poorly absorbed.
The hard shell cap is absorbed in the small intestine, better absorption, and so has high rate of bioavailability, the shelf life is extended and easier storage with less degradation over time.
This means better management of dosing and greater assurance of the dose delivery. Its therefore easier to assess whether the drug delivery is effective and variable dose mgs enable better titration of dosage.
The difference is that the hard shell cap enables doctors to the assured of dosage delivery and so better promotion of the product. This has been the issue that doctors have been wanting solved for some time. AC8 provides the solution from he problems that doctors have identified.
- Forums
- ASX - By Stock
- AC8
- Ann: AusCann Releases Low-dose Form Capsule
Ann: AusCann Releases Low-dose Form Capsule, page-20
-
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AC8 (ASX) to my watchlist
(20min delay)
|
|||||
Last
4.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $17.62M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AC8 (ASX) Chart |
Day chart unavailable
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online